IGF1 and diabetic neuropathy: Our data support the idea that IGF-1–LNP may provide a path to safe and effective gene therapy in neurodegenerative disorders, while the CEBPβ and NFAT1 transcription factors could also represent promising targets manipulating endogenous IGF-1 production for the treatment of diabetic neuropathy.